BOSTON, June 4, 2021 /PRNewswire/ — Delix Therapeutics (the “Company”), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the inaugural members of its Scientific and Strategic Advisory Board. Headquartered in Massachusetts, Delix is creating a new class of neuroplasticity-promoting therapeutics…
